PRELIMINARY PROSPECTUS AVAILABLE ON SEDAR+
NOT FOR RELEASE OR DISTRIBUTION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWS SERVICES.
TORONTO, Nov. 21, 2025 (GLOBE NEWSWIRE) — Conavi Medical Corp. (TSXV:CNVI) (“I tried Medical” or “Company“), a commercial medical device company that develops, manufactures and markets imaging technologies for common minimally invasive cardiovascular procedures, today announced that it has filed a preliminary short form prospectus (“Preliminary Prospectus“) with the securities regulatory authorities in the provinces of British Columbia, Alberta and Ontario in connection with the offering (“Offer“) ordinary shares of the Company (“Ordinary shares“) and/or pre-funded warrants to purchase shares of the Company's common stock (“Pre-funded warrants” and, together with the Common Shares, “Securities“) instead of Common Shares.
The Offering is expected to be made on a commercially reasonable agency basis pursuant to an agency agreement to be entered into between the Company and Bloom Burton Securities Inc. (“Bloom Burton Securities Inc.”).Bloom Burton” or “Agent“). The number of Securities to be distributed, the size of the Offering and the price of each Common Share and Pre-Funded Warrant will be determined through negotiations between the Company and Bloom Burton in the context of the market, and the final terms will be determined at the time of pricing.
The Company intends to use the net proceeds from the Offering to obtain U.S. FDA 510(k) clearance of Novasight's next generation hybrid system and to complete its limited market launch and initiate a broader commercial launch in the United States. The Company also intends to use net proceeds for working capital and other general corporate purposes.
The Offering is expected to close on or about December 12, 2025 (“Closing date“) or such later date as may be mutually agreed upon by the Company and Bloom Burton. The Offering is subject to the Company and the Agent entering into a definitive agency agreement and subject to customary closing conditions, including the receipt of all necessary regulatory and securities exchange approvals, including the approval of the TSX Venture Exchange (the “TSX Venture Exchange”).TSHV“).
In addition, the Securities are expected to be offered by private placement in certain jurisdictions outside Canada in accordance with applicable securities laws.
For more information about the Offering, see the Preliminary Prospectus, a copy of which is available on SEDAR+ at: www.sedarplus.ca.
This press release does not constitute an offer to sell or the solicitation of an offer to buy Securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of such jurisdiction. The securities offered have not been and will not be registered under the United States Securities Act of 1933, as amended (“US Securities Law“), and such securities may not be offered or sold to or for the account or benefit of persons in the United States or US persons absent registration or an applicable exemption from the registration requirements of the United States. “United States” and “US Persons” have the meanings assigned to them in Regulation S under the US Securities Act.
Access to the preliminary prospectus and any amendments thereto will be provided in accordance with securities laws regarding procedures for making available the summary prospectus and any amendments thereto. The preliminary prospectus is available on SEDAR+ at www.sedarplus.ca. Alternatively, an electronic or paper copy of the preliminary prospectus and any amendments to such document may be obtained free of charge from the Agent by email at: [email protected]by calling 416-640-7585 or providing the contact person with your email or address, as applicable. The preliminary prospectus contains important and detailed information about the Company and the Offering. Prospective investors should read the preliminary prospectus before making an investment decision.
About Konavi Medical
Conavi Medical develops, manufactures and markets imaging technologies for common minimally invasive cardiovascular procedures. The patented Novasight Hybrid™ system is the first to combine intravascular ultrasound (IVUS) and optical coherence tomography (OCT) in a single device, allowing simultaneous and co-registering images of the coronary arteries. The first generation Novasight Hybrid™ system has regulatory approval in the United States, Canada, China and Japan. For more information visit conavi.com.
CONTACT:
Christina Cameron
[email protected]
Notice regarding forward-looking statements:
This press release contains forward-looking information or forward-looking statements within the meaning of applicable securities laws with respect to the Company and its business, which may include, without limitation, statements regarding the anticipated terms and jurisdictions of the Offering; securities offered thereunder; the timing of the Offering, including the expected Closing Date; use of proceeds from the Offering; regulatory and exchange approvals, including the listing of the Common Shares offered pursuant to the Offering on the TSXV. All statements or information that are not historical facts, including, but not limited to, statements regarding future estimates, plans, programs, forecasts, projections, goals, assumptions, expectations or beliefs regarding future performance, are “forward-looking information or statements.” Often, but not always, forward-looking information or statements can be identified by the use of words such as “should”, “intends”, “expect”, “believe”, “plan”, “anticipate”, “intend”, “estimate”, “anticipate” or any variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “could”, “might”, “will” or “would” be taken, to happen, to bring about, to bring about or to be achieved. Such statements are based on the Company's management's current expectations and views of future events. They are based on assumptions and are subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this press release may not occur and may differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, those listed in the “Risk Factors” section of the preliminary prospectus and the “Risk Factors” sections of the Company's joint information prospectus dated August 30, 2024 (both of which are set forth in the Company's profile on the website www.sedarplus.ca). Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that could cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
No regulatory authority has approved or approved the contents of this press release. Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
535335320v.6
